MedDataX Logo

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

NCT ID: NCT00567424

Last Updated: 2013-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

NCT01147003

Partial Onset Seizures
COMPLETED PHASE2

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

NCT01167335

Partial Onset Seizures
WITHDRAWN PHASE2

A Study of GWP42006 in People With Focal Seizures - Part A

NCT02369471

Epilepsy Focal Seizures
COMPLETED PHASE2

A Study of GWP42006 in People With Focal Seizures - Part B

NCT02365610

Epilepsy Focal Seizures
COMPLETED PHASE2

A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.

NCT00740623

Epilepsy, Partial, Motor Epilepsy, Complex Partial Epilepsy, Simple Partial +1 more
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GW273225

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confident diagnosis of epilepsy
* Currently on VPA, CBZ or PHT
* \>or= 4 seizures/4 weeks prior to screen

Exclusion Criteria

* Prior lamotrigine use (excluded if treatment discontinued for clinically significant safety reasons (i.e., rash, hypersensitivity)).
* Females of childbearing potential on hormonal contraceptives or hormone replacement therapy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials, MD

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Clinical Trials Call Center

Phoenix, Arizona, United States

Site Status

GSK Clinical Trials Call Center

Sun City, Arizona, United States

Site Status

GSK Clinical Trials Call Center

Little Rock, Arkansas, United States

Site Status

GSK Clinical Trials Call Center

San Jose, California, United States

Site Status

GSK Clinical Trials Call Center

Santa Monica, California, United States

Site Status

GSK Clinical Trials Call Center

Jacksonville, Florida, United States

Site Status

GSK Clinical Trials Call Center

Tallahassee, Florida, United States

Site Status

GSK Clinical Trials Call Center

Tampa, Florida, United States

Site Status

GSK Clinical Trials Call Center

Chicago, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Springfield, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Iowa City, Iowa, United States

Site Status

GSK Clinical Trials Call Center

Wichita, Kansas, United States

Site Status

GSK Clinical Trials Call Center

Baltimore, Maryland, United States

Site Status

GSK Clinical Trials Call Center

Boston, Massachusetts, United States

Site Status

GSK Clinical Trials Call Center

Rochester, Minnesota, United States

Site Status

GSK Clinical Trials Call Center

Saint Cloud, Minnesota, United States

Site Status

GSK Clinical Trials Call Center

Springfield, Missouri, United States

Site Status

GSK Clinical Trials Call Center

St Louis, Missouri, United States

Site Status

GSK Clinical Trials Call Center

Amherst, New York, United States

Site Status

GSK Clinical Trials Call Center

Durham, North Carolina, United States

Site Status

GSK Clinical Trials Call Center

Cleveland, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Toledo, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Medford, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Portland, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Portland, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Dallas, Texas, United States

Site Status

GSK Clinical Trials Call Center

Burlington, Vermont, United States

Site Status

GSK Clinical Trials Call Center

Richmond, Virginia, United States

Site Status

GSK Clinical Trials Call Center

Roanoke, Virginia, United States

Site Status

GSK Clinical Trials Call Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NEC107055

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT00232596 COMPLETED PHASE3
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
NCT00887861 COMPLETED PHASE2
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
NCT03678753 COMPLETED PHASE3
Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures
NCT01721317 TERMINATED PHASE4
Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
NCT02834793 TERMINATED PHASE3
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
NCT06769659 RECRUITING PHASE2
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
NCT02091375 COMPLETED PHASE3
A Study of the Efficacy and Safety of Topiramate as "Add on" Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures
NCT00236704 COMPLETED PHASE3
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
NCT01002820 COMPLETED PHASE2
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
NCT00043901 COMPLETED PHASE4
P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.
NCT00524134 TERMINATED PHASE2/PHASE3
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
NCT02519439 TERMINATED PHASE3
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
NCT02607904 COMPLETED PHASE2
Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures
NCT00975715 COMPLETED PHASE2/PHASE3
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
NCT00866775 COMPLETED PHASE3
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
NCT00425282 COMPLETED PHASE3
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
NCT00236860 COMPLETED PHASE2
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
NCT00236873 COMPLETED PHASE2
A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects
NCT01918735 COMPLETED PHASE1
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
NCT01227902 COMPLETED PHASE3
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
NCT01747915 COMPLETED PHASE3
SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
NCT00136019 COMPLETED PHASE3
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
NCT02072824 COMPLETED PHASE3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142 RECRUITING PHASE3
A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
NCT01393743 COMPLETED PHASE3